Drugs / Moxifloxacin Ophthalmic
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05110001 Background | Aug 2022 → Dec 2024 | Acanthamoeba keratitis, fungal keratitis | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moxifloxacin Ophthalmic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05110001 ↗ |
| Route | Topical | “Topical moxifloxacin 0.5%” NCT05110001 ↗ |